## Original Article Propofol increases Bcl-2 Levels to protect cell from death

#### Luowa Shu<sup>1\*</sup>, Zhiya Chen<sup>2</sup>, Chuxiong Pan<sup>1\*</sup>

<sup>1</sup>Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; <sup>2</sup>State Key Laboratory of Membrane Biology, College of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing 100871, China. \*Equal contributors.

Received September 12, 2016; Accepted September 19, 2016; Epub November 15, 2016; Published November 30, 2016

**Abstract:** Bcl-2 is an important gene of apoptosis research, during the past decade, there has been an increasing interest in the relationship between Bcl-2 and the apoptosis, but only a few studies talk about the relationship between Bcl-2 and propofol, which is a wild use narcotic that can protect cells against various injuries. In the present study, we showed that propofol could down-regulate miR-297a-5p to increased Bcl-2 level. We think this might be a possible mechanism of propofol protecting cell from death. Furthermore, we use an apoptotic drug staurosporine to further improve the propofol's cell protecting function by showing that propofol prevented neurons against staurosporine. Our study supplies a possible mechanism that propofol could regulating Bcl-2 level through miRNA to protect cells.

Keywords: Propofol, microRNA, anesthetics, cell death, Bcl-2

#### Introduction

Bcl-2 family proteins are very important in the regulation of apoptosis, tumorigenesis and cellular responses to anti-cancer therapy, which has been studied intensively for the past decade owing to their importance in the regulation of apoptosis [1, 2]. At the same time, propofol (2, 6-disopropylphenol) is a widely used intravenous short-acting anesthetics [3], which has been also reported in protecting against cerebral ischemia or ischemia-reperfusion, intracerebral hemorrhage, cerebral resuscitation, ischemia of spinal cords, Parkinson's disease (PD) and Alzheimer's disease (AD) [3, 4], but we still don't know the exact mechanisms of propofol's protection. MicroRNAs (miRNAs) are a group of short non-coding RNAs [5]. There are more than one thousand miRNAs identified in mammals [6]. 3'UTR or 5'UTR area interact with a single-stranded miRNA which are the miRNA precursors [7], leading to translation repression or target degradation [8, 9], by miR-NAs which regulate the protein level of the target genes. A single miRNA can conjugate with several hundred target genes, therefore, it may regulate multiple pathways at the same time

[10, 11]. Many miRNAs have demonstrated implications in anesthesia [12-16]. We have a previous study showing that various miRNAs transform propofol treatment into cultured primary mouse hippocampal neurons. After examining 1908 mice microRNAs, we found that there are 40 microRNAs upregulated and 54 microRNAs downregulated with the cutoff as 2 fold change [17].

According to the present study, we reported that in the hippocampal neurons of mice, microRNA named miR-297a-5p, which targets Bcl-2 mRNA 3'UTR, is highly down-regulated with propofol treatment. In addition, we also showed that propofolprevents neuronal fromcelldeath, possibly through reduction in the level of miR-297a-5p. Our results indicate that microRNA regulation is a critical determining factor of propofol protection mechanism.

#### **Experimental procedures**

#### Cell culture and treatments

We culture the primary neurons by using wild type C57 mouse hippocampus, and follow the regulations of Peking University Animal Care

and Use Committee as previously described [18]. In brief, we dissociated the fresh fetal mouse hippocampal tissues into 0.25% trypsin (Invitrogen, Carlsbad, CA) by 20 minutes, then used Dulbecco's Modified Eagle Media (DMEM) mixed by 10% fetal bovine serum (FBS, HyClone, Logan, UT) to terminate. Then the mixture was put in a stationary state for a few minutes, and transferred into another sterilized centrifuge tube and then finally was centrifuged. The pellet was recoiling by 10% FBS. Cells were then plated on poly-,-lysine (Sigma, St. Louis, MO) coated plates or glass coverslips at the density of 3×10<sup>6</sup> cells/ml and added 2 ml neurobasal medium along with B27 (Gibco, 17504-044), GlutaMax (Gibco, 35050-061), and Pen-Strep (Gibco, 15140-22) for every well after 30 minutes. Neurons were incubated in 5% circulating CO<sub>2</sub> at 37°C. Half of the medium was changed every 48 hours. Neurons were treated for experiments at the 7th day in culture. Propofol was added to the medium at 100 nM for 6 hours.

## Real-time PCR

We do the real-time PCR as as per the following procedure described previously [19]. We measured miR-297a-5p in the tissue, serum and cerebrospinal fluid (CSF) by TagMan MicroRNA assay kit according to the manufacturer's instruction (Life Technologies Corp.). In brief, we collected cells and insolated total RNA with TRIGene reagent (GenStar BioSolutions Co., Ltd., Beijing, China). Then reverse transcription was done to be total RNA (2 mg) by using TransScript II First-Strand cDNA Synthesis SuperMix (Beijing TransGen Biotech Co., Ltd., Beijing, China). We only used TransStart Green qPCR SuperMix UDG (Beijing TransGen Biotech Co., Ltd., Beijing, China) to do the real-time PCRs. We ran the sample as triplicate and determine the average for real-time PCR guantifications. In order to use the Ct method to compare the relative quantification, the amplification efficiency of target and housekeeping gene must be approximately equal. After using the comparative Ct method to finish quantification, we normalized the expression levels for the target gene by the GAPDH of each sample  $[2^{-\Delta Ct}=2^{-(Ct(target gene)-Ct(GAPDH))}]$ . Amplification was done for 45 cycles at 95°C for 30 s, 59°C for 30 s, 72°C for 30 s, 95°C for 1 min, 59°C for 30 s and 95°C for 30 s.

# Sources of reagents and sequences of miRNAs and 3'UTR

Mouse miR-297a-5p (5'-AUGUAUGUGUGCAUG-UGCAUGU-3'), scramble microRNA control (5'-GTGTAACACGTCTATACGCCCA-3'), mimic miR-297a5p (5'-UUGGAAGGGCGTCTAUGCAUGU-3'), miR-297a-5p inhibitor (5'-AACCUUCCCGUAUG-ACGUACA-3') and mutant miR-297a-5p (5'-AU-GUAUGUGUGCAUGACGUACA-3'), complementary sequence (5'-ACATACA-3') were all purchased from Qiagen. Several altered mouse Bcl-2 mRNA 3'UTR sequences used were as following: mutant Bcl-2 mRNA 3'UTR: 5'-TGTAT-GT-3'; MAP2-3'UTR: 5'-CATATTCATTCTTTACAAA-CCATAG-3'. All WT and modified 3'UTR sequences were cloned into pLenti-Luc-UTR or pLenti-EGFP-UTR vector backbone (Abm). MicroRNAs were transfected into SH-Sy5y cells with HiPerFect Transfection Agent (Qiagen).

We used the 100× stored propofol (Sigma) and staurosporine (STS, Sigma) and diluted with the culture medium before useing it. One month old C57 mice were treated with propofol (200 mg/kg) by intraparietal injection (i.p.). Cultured cells were treated with 2% propofol for 6 hours before assays.

# Western blots and measurement of neuronal cell death

We do western blots by following the protocol described previously [18]. In brief, we diluted anti-Bcl-2 (Abcam) and actin (Sigma) antibodies at 1:1000 for Western blots as primary antibodies. Because actin is the house keeping gene, the relative density was calculated by the total absolute density of Bcl-2/actin control. We measured the cell death with terminal deoxynucleotidyl transferase-biotin dUTP nick-end labeling (TUNEL) staining performed using the *in situ* cell death detection kit I which described by the manufacturer (Roche) [18].

## Luciferase reporter assay

We used the Dual-Luciferase Reporter Assay System kit (E1910, Promega) to investigate the effect of miR-297a-5p on Bcl-2 expression. In the meantime, we used co-transfected with the wild-type, mutant, scramble, mimic and inhibitor to miR-297a-5p into SH-Sy5y cells as the constructs of the firefly (Photnus pyralis) luciferase gene downstream of the Bcl-2 3'UTR.

#### Mmu-miR-297a-5p

#### AUGUAUGUGUGCAUGUGCAUGU

#### Bcl-2 mRNA 3'UTR

3061 ATCGAGAAGA GCAGCCCAAT GCCCTCCAGA GCCCCAGTAC CCGCCCAGGC TCTCTGAGAG 3121 ATGGCAAAAA AAACAGAGAG GTTGATCTTC AGTGATTCCT CAGGGCCTGA ACTTGCGTGA 3181 AGGCTTGAGA TGTCCATGAG AGCCACAGTT AAGGGAGCAC TTTCATGTAG TTCAAGTAAA 3241 ACCCTCCATC CTGTCCAGCT CGCTTGTCTC TGGATGTTTG GGTGTGGCCT TTATTCATAC 3301 ATACATACAT TITTTCCACA GGCATATTCT TATTTATTAC ATCTAAGAGC ATTGCTGGGT 3361 CTAGGAAAGG GGGAAGCAGG GTTTAGGAAG TGCTCATAAG CCAGGAGGGA TTATAATAAT 3421 CAGGACTGAA TGTAGATAAT GGGTGGCAGT ACCCACATGT GTAGGTCCCA CACTGAATAG 3481 AATAGGCAGA ATTGTGAATA GCCCGTGTTT GTAATGGAGC CTAGACTAAA ACAACTCATA 3541 AATGTGAGCT TCAACTCTAA CTGTGCTTTG AAGGTGATGG GTGTCTCTAT ACTTCCTTAT 3601 CAGTTACAGT TAGAAATGTA CACCTACCCT ATCAGGAAAA AATAACAGGA AAAGGTTGAA 3661 ATATAAGCCA GTCTAAGGAA ATTAGGGAGC CACTAAAGTT CTCTTCTGAG CTTATACTAT 3721 GGTCTCTATT GCAGCTCAGA CAAATATGAT CACACACTTT TTAAGAAATA CAATTCTCCA 3781 TTGTCGGGCC CATGAAGGCT CTGATCTGAT CTGTATTGTT GCCCAATTTG GGTCTTTCAG 3841 GGATTTTTCT ATGCCATTAT TATAGGGACA AAGGACACTT GTTATGAGGT GGGAGAGATG 3901 AAGAATTCTT ACATGAGTAG AACATTTCCT AGATTGGGCC AGGGTGTGAA GGTCTTCAGC 3961 AAAATCAAGG CTGTGAGAAG TGAGGGACCT TTATGGGGGT CAAAGTTATG TTCGCCTGAG 4021 GACTTTTTGC AAGAAGCAAG GAAGCTCTAT GGTACATTTA TACTCCAGGG ACATTGACCT 4081 AGTTCAAAGT CTGGCTTAAT ATGGTCAAGC AATAGCATAT GTTTCAAGTT GGATATGGCT 4141 AATGAGTGTT TAAACAGTAA GTTTGACATT TTAACCAACA GGGTATTTAA ACAACAACTT 4201 TCCAGTTGGT AGGGACATCT GTTTCTCTCT GTTTATTATA CACAACATAG AAAAAATTCA 4261 ATAAGATTGA ATTAAGTAAA ACATTGTGAG ACTGAGTTAG GTAAACGATT GTGGCAGTCC 4321 CTTAGCCTTG GCCAGGGAAT TATTCAATCC GCTATAGACA TCTGTGCACT GTGCATCTCT 4381 CCAGGCATGA AGAAAACCAG GTAGAGGGCA GATGGCACCT GAGCACTTCA TCCTGGATAT 4441 CTAAGAAGAA TAACATAAAG CCAGTGTTCC ATGCACCAAG TCCAGTACAG AAGACAAAAA 4501 GAGTCACAGA AGATGGAAAA GCTAGCTAAT CAGAAATCCT GGGAATGTTA AGTGTGCCGG 4561 CCATGTGGCT ATGCGGCAAT GCCTGTACCT TCCCACTTGG GAACCTGCAG TGGGCCCTCC 4621 AGCTGGCTCC CTTCATGAAA TCCTCCCCTC CGAGATAACA TCTGAAGGAT TGATGGCAGA 4681 TTCAGTTTCC ATTAGGAGAT ATTTTCCTTT GGAGACAGGG GTTCTCTATT AAAATATCTT 4741 CTTAGGTTTT CAGCTAAACT TTGCTTTGGC TTCAGCTATA GTGGGGTTCT TTCTAAGTAA 4801 AGTAATGTTC AAATAAGTGT TTTGTATTGG AAGCTTTGTT ATCAAGATTT TCATACTTAT 4861 ATCCATGGGC TGCTTTTAAG GTTGATACTT TTAGGCGTGG CTGATGCCTA TAGCACTGTA 4921 CATACAAGAA ATATATAAGT GTATTTGGCA TACTTAAGGT AAAATAAGTC TCCAGTTGGC 4981 TACTGTTACA TATAATGGCT CTTTGTTTGT GTTGTTAGAA AACATTACAT TGCCATTAAC 5101 AAA

Figure 1. Sequence alignment of mouse miR-297a-5p and Bcl-2 mRNA 3'UTR region. The red highlighted parts shows the complementary regions.

As indicated by the manufacturer, firefly luminescence was detected. In order to control the transfection efficiency, the *Renilla reniformis* luciferase construct was co-transfected into the cells. The activity was corrected for the protein concentration of each sample and expressed as [(firefly/renilla luciferase) \*10,000]. The luminescence was expressed as relative light units [20].

### Statistical evaluation

We used one-way analysis of variances (ANOVA) by the Sheffé's test which has statistical significance. A p value of less than 0.05 indicated statistical significance.

### Results

Bcl-2 mRNA 3'UTR wasatarget of miR-297a-5p

According to the miRNA target prediction tool website (http://www.microrna.org/microrna/

home.do), one complementary sequence for miR-297a-5p is present in the 3'UTR of Bcl-2 mRNA in mice (Figure 1, highlighted with red). After treating it with propofol in the hippocampal tissues which camefrom 1 month old mice, miR-297a-5p was decreased (Figure 2A). Previous studies have shown that miRNAs can be secreted into the CSF and plasma [21]. Therefore, we observed that miR-297a-5p levelsweredown-regulatedin the CSF and plasmaafter propofol treatment (Figure 2A).

In SH-Sy5y cells, luciferase reporter assays were performed with the expression of firefly regulated by miR-297a-5p which is the complementary region of Bcl-2 mRNA 3'UTR, and used renilla as an internal control for transfection efficiency. We found that miR-297a-5p induced a dosedependent inhibition of luciferase activity, whereas mutant miR-297a-5p and scramble control miRNA had no effect (Figure 2B). The mimic of miR-297a-5p obviously inhibited

the luciferase activity, although the inhibitor of miR-297a-5p increased the luciferase activity (**Figure 2B**). In SH-Sy5y cells, EGFP reporter assay confirmed the similar inhibitory effect of miR-297a-5p to Bcl-2 mRNA 3'UTR (**Figure 2C**).

We then mutated the Bcl-2 mRNA 3'UTR complementary sequence and performed luciferase assay and EGFP reporter assay with both scramble control miRNA and miR-297a-5p. Our results showed that miR-297a-5p only suppressed the luciferase activity or EGFP fluoresence with WT Bcl-2 mRNA 3'UTR, but did not significantly inhibit with mutant 3'UTR (Figure 2D and 2E), which suggested the specificity of the interaction between miR-297a-5p and Bcl-2 mRNA 3'UTR. Further more, in order tofurther confirm that the Bcl-2 mRNA 3'UTR was one of the targets for miR-297a-5p, we mutanted Bcl-2 mRNA 3'UTR with the putative complementary binding domain sequence (BD), 2 repeats of the BD sequence (2BD) and 3 repeats of the BD



Figure 2. Propofol was protective against cell death. A. After treating with propofol, miR-297a-5pwas decreased in the hippocampal tissues, CSF and plasma in the mice. B. The dose response of miR-297a-5p on luciferase reporter assay in SH-Sy5y cells. C. The dose response of miR-297a-5p on EGFP reporter assay in SH-Sy5y cells. D. MiR-297a-5p reduced the luciferase activity with WT Bcl-2 mRNA 3'UTR, but not with mutant Bcl-2 mRNA 3'UTR. E. MiR-297a-5p reduced the EGFP reporter activity with WT Bcl-2 mRNA 3'UTR, but not significantly with mutant Bcl-2 mRNA 3'UTR. F. MiR-297a-5p did not alter the expression with unrelated MAP2 mRNA 3'UTR. Within Bcl-2mRNA 3'UTR constructed with 2 times or 3 times of the putative binding domain (2BD, 3BD) of each binding site, miR-297a-5p decreased luciferase activity remarkably in a dose dependent manner. G. Time course of miR-297a-5p inhibition on Bcl-2mRNA 3'UTR. H. Western blot of Bcl-2 showed that mimic to miR-297a-5p (lane 2) reduced whereas inhibitor to miR-297a-5p (lane 4) increased the Bcl-2 level. Mutant miR-297a-5p (lane 3) did not alter Bcl-2 level. I. Statistics of H. Data represent Mean ± SE (n=3 for each group). \*\*: P<0.01 compared with control. J. Western blot of Bcl-2 showed that propofol increased the Bcl-2 level. K. Statistics of J. Data represent Mean ± SE (n=3 for each group). \*\*: P<0.01 compared with control. L. In cultured neurons, we compare the cell death rate results ofseveral different treatments such as adding propofol at 2%, propofol at 2% and Bcl-2 inhibitor, STS only, STS and propofol at 2%, and STS, propofol at 2% and Bcl-2 inhihitor in the culture medium, we measured cell death 6 hours after treatment. Data represent Mean ± SE (n=3 for each group). \*\*: P<0.01 compared with control.

sequence (3BD) for each putative binding site. Luciferase reporter system showed that miR-297a-5p did not inhibit the luciferase activity regulated by unrelated MAP2 mRNA 3'UTR (Figure 2F). luciferase activity was greatly reduced in a BD dose-dependent manner where in Bcl-2 mRNA 3'UTR (Figure 2F). Time course study showed that luciferase acitivity was inhibited by miR-297a-5p from 12 hours after treatment and kept at almost the same inhibition levels after 12 hours (Figure 2G). Western blotting of total Bcl-2 with miR-297a-5p, inhibitor to miR-297a-5p, and mutant miR-297a-5p indicated that miR-297a-5p indeed decreased Bcl-2 protein level (Figure 2H and 21), whereas inhibitor to miR-297a-5p increased Bcl-2 (Figure 2H and 2I).

## Propofolprevent cell death by up-regulation the bcl-2 level

It is well-known that Bcl-2 family proteins areinvolved in regulation of cell death, especially apoptosis [1, 2]. We then examined the vulnerability to various injury in cultured neurons with or without propofol treatment. Our data showed that STS could induce severe cell death in untreated neurons than in propofol treated neurons [22, 23]. After that, we did a western where western blot of Bcl-2 showed that propofol increased the Bcl-2 level (Figure 2J and 2K). In cultured neurons, neuronal toxicity was induced by STS, we compared the cell death rate cell death rate results of five different treatments such as (i) adding propofol at 2%, (ii) addingpropofol at 2% and Bcl-2 inhibitor, (iii) adding STS only, (iv) adding STS and propofol at 2%, and (v) adding

STS. Propofol at 2% and Bcl-2 inhihitor in the culture medium remarkably decreased cell death at 6 hours after treatment (**Figure 2L**).

## Discussion

As we know, the earliest metazoan that was analysed withregards to the Bcl-2 gene was the sponge [24], and so far Bcl-2 gene orthologues have been identified in all metazoan animals [25]. During the past few years, people found some viral gene products the signature helical fold of Bcl-2, where it functions in apoptosis regulation [26-28]. Moreover, propofol as an anesthetic has been widely used in short-acting anesthesia andprotects cells against various insults by increasing level of Bcl-2, which is an anti-apoptotic protein, and decreasing the level of pro-apoptotic protein Bax. Our study has developed another possible mechanism, whichis that propofol regulating Bcl-2 level through miRNA prevents cell death.

In studies with those mechanisms, we found that neurons with propofol treatment could cause miR-297a-5p to be down-regulated. Besides that, miR-297a-5p targets 3'UTR of Bcl-2 mRNA and the decrease of miR-297a-5p increases Bcl-2 level in neurons. Propofol could protect against cell death induced by STS. However the mechanism of propofol protection has not been made fully clear yet. One possible explanation is that propofol can decrease miR-297a-5p level, which targets 3'UTR of Bcl-2 mRNAand increases the level of Bcl-2. Because the activation of Bcl-2 reduces cell death and apoptosis, increasing Bcl-2 level could prevent cell death. Our current data showed consistancy with the previous observation which isthat propofol may reduce cell death through increase of Bcl-2 [29]. In conclusion, our study indicates that propofol could prevent cell death by up-regulation the Bcl-2 level through decreasing the miR-297a-5p level which target the 3'UTR of Bcl-2 mRNA.

## Acknowledgements

This work was supported by the National Science Foundation of China (NSFC) Research Grant (81301131, 81571037 and 81671044).

## Disclosure of conflict of interest

None.

## Authors' contribution

L.S., and Z.C. performed all the experiments and analyzed the data. C.P. conceptualized the study, performed analyses and drafted the manuscript.

Address correspondence to: Dr. Chuxiong Pan, Department of Anesthesiology, Beijing Tongren Hospital, Beijing 100730, China. E-mail: pandedao@126.com

## References

- Youle RJ and Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
- [2] Delbridge AR, Grabow S, Strasser A and Vaux DL. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer 2016; 16: 99-109.
- [3] Fan W, Zhu X, Wu L, Wu Z, Li D, Huang F and He H. Propofol: an anesthetic possessing neuroprotective effects. Eur Rev Med Pharmacol Sci 2015; 19: 1520-1529.
- [4] Zhang Y, Zhen Y, Dong Y, Xu Z, Yue Y, Golde TE, Tanzi RE, Moir RD and Xie Z. Anesthetic propofol attenuates the isoflurane-induced caspase-3 activation and Abeta oligomerization. PLoS One 2011; 6: e27019.
- [5] Lagos-Quintana M, Rauhut R, Lendeckel W and Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001; 294: 853-858.
- [6] Delay C, Mandemakers W and Hebert SS. MicroRNAs in Alzheimer's disease. Neurobiol Dis 2012; 46: 285-290.
- Peters L and Meister G. Argonaute proteins: mediators of RNA silencing. Mol Cell 2007; 26: 611-623.
- [8] Eulalio A, Huntzinger E, Nishihara T, Rehwinkel J, Fauser M and Izaurralde E. Deadenylation is a widespread effect of miRNA regulation. RNA 2009; 15: 21-32.
- [9] Meister G. miRNAs get an early start on translational silencing. Cell 2007; 131: 25-28.
- [10] Baek D, Villen J, Shin C, Camargo FD, Gygi SP and Bartel DP. The impact of microRNAs on protein output. Nature 2008; 455: 64-71.
- [11] Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R and Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008; 455: 58-63.
- [12] Ishikawa M, Tanaka S, Arai M, Genda Y and Sakamoto A. Differences in microRNA changes of healthy rat liver between sevoflurane and propofol anesthesia. Anesthesiology 2012; 117: 1245-1252.

- [13] Tanaka S, Ishikawa M, Arai M, Genda Y and Sakamoto A. Changes in microRNA expression in rat lungs caused by sevoflurane anesthesia: a TaqMan(R) low-density array study. Biomed Res 2012; 33: 255-263.
- [14] Werner W, Sallmon H, Leder A, Lippert S, Reutzel-Selke A, Morgul MH, Jonas S, Dame C, Neuhaus P, Iacomini J, Tullius SG, Sauer IM and Raschzok N. Independent effects of sham laparotomy and anesthesia on hepatic microR-NA expression in rats. BMC Res Notes 2014; 7: 702.
- [15] Jiang XL, Du BX, Chen J, Liu L, Shao WB and Song J. MicroRNA-34a negatively regulates anesthesia-induced hippocampal apoptosis and memory impairment through FGFR1. Int J Clin Exp Pathol 2014; 7: 6760-6767.
- [16] Lu Y, Jian MY, Ouyang YB and Han RQ. Changes in rat brain MicroRNA expression profiles following sevoflurane and propofol anesthesia. Chin Med J (Engl) 2015; 128: 1510-1515.
- [17] Luowa Shu XY, Xu Cui, Dingxi Zhou, Junfa Li, Tianzuo Li, Chuxiong Pan. Propofol treatment alters microRNA profiling in neurons. Int J Clin Exp Med 2016; 9: 11292-11298.
- [18] Cui J, Wang Y, Dong Q, Wu S, Xiao X, Hu J, Chai Z and Zhang Y. Morphine protects against intracellular amyloid toxicity by inducing estradiol release and upregulation of Hsp70. J Neurosci 2011; 31: 16227-16240.
- [19] Wang Y, Cui J, Sun X and Zhang Y. Tunnelingnanotube development in astrocytes depends on p53 activation. Cell Death Differ 2011; 18: 732-742.
- [20] Zhang Y, Champagne N, Beitel LK, Goodyer CG, Trifiro M and LeBlanc A. Estrogen and androgen protection of human neurons against intracellular amyloid beta1-42 toxicity through heat shock protein 70. J Neurosci 2004; 24: 5315-5321.
- [21] Chan AW and Kocerha J. The Path to microRNA Therapeutics in psychiatric and neurodegenerative disorders. Front Genet 2012; 3: 82.

- [22] Zhang Y, Goodyer C and LeBlanc A. Selective and protracted apoptosis in human primary neurons microinjected with active caspase-3, -6, -7, and -8. J Neurosci 2000; 20: 8384-8389.
- [23] Cui J, Chen Q, Yue X, Jiang X, Gao GF, Yu LC and Zhang Y. Galanin protects against intracellular amyloid toxicity in human primary neurons. J Alzheimers Dis 2010; 19: 529-544.
- [24] Wiens M, Krasko A, Muller Cl and Muller WE. Molecular evolution of apoptotic pathways: cloning of key domains from sponges (Bcl-2 homology domains and death domains) and their phylogenetic relationships. J Mol Evol 2000; 50: 520-531.
- [25] Aouacheria A, Brunet F and Gouy M. Phylogenomics of life-or-death switches in multicellular animals: Bcl-2, BH3-Only, and BNip families of apoptotic regulators. Mol Biol Evol 2005; 22: 2395-2416.
- [26] Aoyagi M, Zhai D, Jin C, Aleshin AE, Stec B, Reed JC and Liddington RC. Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci 2007; 16: 118-124.
- [27] Douglas AE, Corbett KD, Berger JM, McFadden G and Handel TM. Structure of M11L: a myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2. Protein Sci 2007; 16: 695-703.
- [28] Kvansakul M, van Delft MF, Lee EF, Gulbis JM, Fairlie WD, Huang DC and Colman PM. A structural viral mimic of prosurvival Bcl-2: a pivotal role for sequestering proapoptotic Bax and Bak. Mol Cell 2007; 25: 933-942.
- [29] Cui DR, Wang L, Jiang W, Qi AH, Zhou QH and Zhang XL. Propofol prevents cerebral ischemiatriggered autophagy activation and cell death in the rat hippocampus through the NFkappaB/p53 signaling pathway. Neuroscience 2013; 246: 117-132.